KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Research & Development (2016 - 2025)

Pacira BioSciences has reported Research & Development over the past 16 years, most recently at $37.5 million for Q4 2025.

  • Quarterly results put Research & Development at $37.5 million for Q4 2025, up 56.73% from a year ago — trailing twelve months through Dec 2025 was $117.0 million (up 43.37% YoY), and the annual figure for FY2025 was $117.3 million, up 43.81%.
  • Research & Development for Q4 2025 was $37.5 million at Pacira BioSciences, up from $26.0 million in the prior quarter.
  • Over the last five years, Research & Development for PCRX hit a ceiling of $37.5 million in Q4 2025 and a floor of $11.6 million in Q3 2021.
  • Median Research & Development over the past 5 years was $19.4 million (2022), compared with a mean of $20.8 million.
  • Biggest five-year swings in Research & Development: soared 109.04% in 2022 and later fell 28.38% in 2023.
  • Pacira BioSciences' Research & Development stood at $15.5 million in 2021, then rose by 12.83% to $17.5 million in 2022, then grew by 11.19% to $19.5 million in 2023, then rose by 22.78% to $23.9 million in 2024, then soared by 56.73% to $37.5 million in 2025.
  • The last three reported values for Research & Development were $37.5 million (Q4 2025), $26.0 million (Q3 2025), and $28.2 million (Q2 2025) per Business Quant data.